Stonegate Capital Partners Updates Coverage on Sky Harbour Group Corporation (NYSE: SKYH) 1Q26
Sky Harbour’s 1Q26 moved the investment focus toward lease-up, Phase II operating leverage, and funded project conversion. The key read-through was stronger re-lease pricing, OPF Phase II opening 68% leased, and a clearer path from construction spend to run-rate EBITDA. Over the next several quarters, investor focus should center on occupancy gains at newer campuses, […]
Stonegate Capital Partners Updates Coverage on Aquafil S.p.A (BIT: ECNL) 1Q26
Aquafil’s 1Q26 was better than the revenue decline implies, with cost savings, production efficiencies, and operating cash generation reinforcing the FY25 margin reset. Revenue declined 7.1% to €133.8M, largely reflecting raw material-linked pricing resets and FX, while first-grade volumes increased 0.9% y/y. EBITDA increased 15.8% to €19.8M, representing a 14.8% EBITDA margin versus 11.9% in […]
Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (NASDAQ: ACOG) 1Q26
Alpha Cognition’s 1Q26 strengthened the ZUNVEYL launch thesis in long term care, with net product revenue increasing 40% q/q to $3.5M, March marking the strongest demand month since launch, and April tracking above March. More importantly, adoption quality continued to improve across prescribers and facilities, suggesting ZUNVEYL is moving further beyond initial trial use and […]
Stonegate Updates Coverage on Pedevco Corp (NYSE: PED) 1Q26
PEDEVCO’s 1Q26 was the first full-quarter proof point that Juniper expanded the Company’s earnings base, not just its acreage footprint, with production of 8,091 Boe/d ahead of internal expectations. Results were driven by better-than-planned D-J performance and a full quarter of acquired contribution, while the reported net loss was largely hedge-accounting driven. Moving forward, the […]
Stonegate Initiates Coverage on Nine Energy Services, Inc. (NYSEAM: NINE)
NINE’s 1Q26 print marked an important transition quarter as the Company emerged from bankruptcy and reset its financial foundation. GAAP comparability was limited by Chapter 11 emergence and fresh-start accounting, while adjusted EBITDA was burdened by severe January/February weather and a $5.5M non-cash inventory write-down that management did not add back. The read-through was positive, […]
Stonegate Capital Partners Updates Coverage On Aemetis, Inc. (Nasdaq: AMTX) 1Q26
Aemetis’ 1Q26 further supports the transition from project buildout toward recurring low-carbon fuel monetization, with quarterly 45Z recognition and improving RNG economics beginning to appear in reported results. Revenue increased 27% y/y to $54.6M, gross profit improved to $2.8M from a $5.1M loss, and adj. EBITDA improved to negative $1.3M from negative $10.7M. The key […]
Stonegate Capital Partners Updates Coverage On Surf Air Mobility Inc. (NYSE: SRFM) 1Q26
SRFM’s 1Q26 results showed continued execution under the transformation plan, with revenue of $25.6M at the high end of guidance and up 9% y/y, while adjusted EBITDA loss of $12.3M outperformed guidance for a loss of $15.5M to $13.5M. Results were supported by improved On Demand private charter margins, cost controls across airline operations, and […]
Stonegate Capital Partners Updates Coverage on MarketWise (NASDAQGM: MKTW) 1Q26
MKTW’s 1Q26 improved the forward setup by showing that the FY25 recovery is broadening into paid subscriber growth, higher ARPU, and reaffirmed FY26 cash flow targets. The reported GAAP revenue decline and negative CFFO understated underlying operating trends; revenue recognition continues to reflect older billings cohorts given the multi-year recognition structure of subscriptions, while CFFO […]
Stonegate Capital Partners Updates Coverage on Viemed Healthcare, Inc. (NASDAQ: VMD) 1Q26
Viemed’s 1Q26 results showed improving growth quality, not just reported scale. Sleep, resupply, and maternal health are becoming larger contributors, reducing reliance on legacy ventilation and improving capital efficiency. At the same time, ventilation appears to be moving through the NCD transition, with better new-start activity and improving compliance, though turnover continues to pressure census. […]
Stonegate Capital Partners Updates Coverage on OS Therapies Inc. (NYSE: OSTX)
OS Therapies advanced materially through late-stage regulatory and commercialization preparation as OST-HER2 moved from Phase 2b supported planning toward a more defined global approval pathway in recurrent, fully resected, pulmonary metastatic osteosarcoma. The key change is greater regulatory clarity: EMA initiated rolling review of the OST HER2 Conditional Marketing Authorization dossier, while EMA and Australia’s […]